Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden

References

• Bjørneboe M, Iversen O, Olsen S. Infective hepatitis and toxic jaundice in a municipal hospital during a five-year period: incidence and prognosis. Acta Med Scand 1967; 182: 491–501
   PubMedGoogle Scholar
• Malchow-Møller A, Matzen P, Bjerregaard B, Hilden J, Holst-Christensen J, Staehr Johansen T, et al. Causes and characteristics of 500 consecutive causes of jaundice. Scand J Gastroenterol 1981; 16: 1–6
   PubMed Web of Science ®Google Scholar
• Whitehead MW, Hainsworth I, Kingham JGC. The causes of obvious jaundice in South West Wales: 2000. Gut 2001; 48: 409–13
   PubMed Web of Science ®Google Scholar
• Björnsson E, Ismael S, Nejdet S, Kilander A. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003; 38: 86–94
   PubMed Web of Science ®Google Scholar
• Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947–54
   PubMed Web of Science ®Google Scholar
• Wei G, Bergqvist A, Broome U, Björnsson E. Acute liver failure in Sweden: etiology and prognosis [abstract 48]. Scand J Gastroenterol 2004; 240(39 Suppl)36
   Google Scholar
• Williams R. Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis 1996; 16: 343–8
   PubMed Web of Science ®Google Scholar
• O'Grady JG, Alexander GJM, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439–45
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Carithers RL, Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21: 240–52
   PubMed Web of Science ®Google Scholar
• Olsson R, Brunlof G, Johansson ML, Persson M. Drug-induced hepatic injury in Sweden. Hepatology 2003; 38: 531–2
   PubMed Web of Science ®Google Scholar
• Böttiger LE, Furhoff AK, Holmberg L. Fatal reactions to drugs. Acta Med Scand 1979; 205: 451–6
   PubMed Web of Science ®Google Scholar
• Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323–30
   PubMed Web of Science ®Google Scholar
• Benichou C. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol 1990; 11: 272–6
   PubMed Web of Science ®Google Scholar
• Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. Br Med J 1999; 319: 1541–4
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451–5
   PubMed Web of Science ®Google Scholar
• Böttiger LE, Westerholm B. Adverse drug reactions during treatment of urinary tract infections. Eur J Clin Pharmacol 1977; 11: 439–42
   PubMed Web of Science ®Google Scholar
• Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years’ experience. N Z Med J 1996; 109: 315–9
   PubMed Web of Science ®Google Scholar
• Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232: 133–8
   PubMed Web of Science ®Google Scholar
• Brandsaeter B, Hockerstedt K, Friman S, Ericzon BG, Kirkegaard P, Isoniemi H, et al. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation: 12 years’ experience in the Nordic countries. Liver Transpl 2002; 8: 1055–62
   PubMed Web of Science ®Google Scholar
• Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992; 15: 154–61
   PubMed Web of Science ®Google Scholar
• Devereaux BM, Crawford DH, Purcell P, Powell LW, Roeser HP. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic?. Eur J Clin Pharmacol 1995; 49: 81–5
   PubMed Web of Science ®Google Scholar
• Fairley CK, McNeil JJ, Desmond P, Smallwood R, Young H, Forbes A, et al. Risk factors for development of flucloxacillin associated jaundice. Br Med J. 1993; 23: 233–5
   Web of Science ®Google Scholar
• McNeil JJ, Grabsch EA, McDonald MM. Postmarketing surveillance: strengths and limitations. The flucloxacillin-dicloxacillin story. Med J Aust 1999; 170: 270–3
   PubMed Web of Science ®Google Scholar
• Ibanez L, Perez E, Vidal X, Laporte JR. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002; 37: 592–600
   PubMed Web of Science ®Google Scholar
• Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22: 820–7
   PubMed Web of Science ®Google Scholar
• James O. Drugs and the ageing liver. J Hepatol 1985; 1: 431–5
   PubMed Web of Science ®Google Scholar
• Lewis JH, Zimmerman HJ. Drug-induced liver disease. Med Clin North Am 1989; 73: 775–92
   PubMed Web of Science ®Google Scholar